Ventyx Biosciences to Participate in the Piper Sandler 37th Annual Healthcare Conference

Rhea-AI Summary

Ventyx Biosciences (Nasdaq: VTYX) said company executives will participate in a fireside chat at the Piper Sandler 37th Annual Healthcare Conference in New York on Wednesday, December 3, 2025 from 4:00–4:25 PM ET. A live webcast will be available on the company's Investors and News webpage and a replay will be posted for 30 days after the event.

SAN DIEGO, Dec. 01, 2025 (GLOBE NEWSWIRE) -- Ventyx Biosciences, Inc. (Nasdaq: VTYX) (“Ventyx”, “Company”), a clinical-stage biopharmaceutical company focused on developing innovative oral therapies for patients with inflammation-mediated cardiovascular and neurodegenerative diseases, today announced that Company executives will participate in a fireside chat at the upcoming Piper Sandler 37^th Annual Healthcare Conference in New York.

Piper Sandler 37^th Annual Healthcare Conference details:
Fireside Chat
Date: Wednesday, December 3, 2025
Time: 4:00 – 4:25 PM ET

A live webcast of the event will be available In the Investors and News section of the Ventyx website at https://ventyxbio.com/. A webcast replay will also be available on this website after the conclusion of the event for 30 days.

About Ventyx Biosciences

Ventyx Biosciences is a clinical-stage biopharmaceutical company developing innovative oral therapies for patients inflammation-mediated cardiovascular and neurodegenerative diseases. Our expertise in medicinal chemistry, structural biology, and immunology enables the discovery of differentiated oral small molecule therapeutics for conditions with high unmet medical need, and our extensive experience in clinical development allows the rapid progression of these drug candidates through clinical trials.

Our portfolio of NLRP3 inhibitors includes VTX2735, a peripherally restricted NLRP3 inhibitor in Phase 2 development for recurrent pericarditis, and VTX3232, a CNS-penetrant NLRP3 inhibitor that recently completed a Phase 2 study in participants with obesity and cardiovascular risk factors and a Phase 2a study in Parkinson’s disease. Our inflammatory bowel disease portfolio includes two Phase 2 compounds: tamuzimod (VTX002), an S1P1R modulator and VTX958, a TYK2 inhibitor.

For more information on Ventyx, please visit our website at https://ventyxbio.com.

Investor Relations Contact:
Alex Schwartz
Vice President, Investor Relations and FP&A
Ventyx Biosciences, Inc.
IR@ventyxbio.com

FAQ

When will Ventyx Biosciences (VTYX) present at the Piper Sandler 2025 conference?

Ventyx executives will present on December 3, 2025 from 4:00–4:25 PM ET.

Where can I watch the Ventyx (VTYX) fireside chat webcast for the Piper Sandler conference?

The live webcast and a 30‑day replay will be available in the Investors and News section of Ventyx's website.

What topics will Ventyx (VTYX) likely cover in the December 3, 2025 fireside chat?

The company will discuss its clinical-stage programs and oral therapies for inflammation-mediated cardiovascular and neurodegenerative diseases.

How long will the Ventyx (VTYX) presentation at Piper Sandler last on December 3, 2025?

The scheduled fireside chat is 25 minutes long (4:00–4:25 PM ET).

Will a replay of Ventyx's (VTYX) Piper Sandler presentation remain available after the event?

Yes, a webcast replay will be posted on Ventyx's website and remain accessible for 30 days after the event.